台股 » 個股 » 中裕 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

中裕

(4147)
可現股當沖
  • 股價
    77.8
  • 漲跌
    ▼1.1
  • 漲幅
    -1.39%
  • 成交量
    475
  • 產業
    上櫃 生技醫療類股
  • 321人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
中裕 (4147)籌碼相關-福勝 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

福勝 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/05/0800.00178.8079.10-11,862-0.05%
2025/05/07177.9000.0079.0011,8700.05%
2025/05/0600.00280.0080.20-21,873-0.11%
2025/04/3000.00282.5081.80-21,875-0.11%
2025/04/24280.10581.0079.60-31,879-0.16%
2025/04/21175.2000.0075.3011,8940.05%
2025/04/15178.20578.1077.80-42,347-0.17%
2025/04/1100.00272.5073.80-22,377-0.08%
2025/04/08571.3000.0071.3052,3310.21%
2025/03/1900.00194.0092.80-12,098-0.05%
2025/03/13392.0000.0091.6032,0990.14%
2025/03/0600.00597.1094.30-51,957-0.26%
2025/02/241099.501103.0099.3091,7960.50%
2025/02/21299.852105.5098.9001,7270.00%
2025/02/2000.001299.3099.70-121,553-0.77%
2025/02/177101.506107.2597.1011,4400.07%
2025/02/14199.2014.398.6898.90-13.31,226-1.09%
2025/02/1200.00193.0093.00-11,152-0.09%
2025/01/2100.00584.7084.50-51,131-0.44%
2025/01/1300.00298.1089.90-21,132-0.18%
2025/01/09489.1300.0087.5041,0140.39%
2025/01/0700.00192.4092.70-1649-0.15%
2025/01/0300.00288.9088.30-2600-0.33%
2025/01/0200.00288.0087.00-2591-0.34%
2024/12/0600.00289.4087.60-2573-0.35%
2024/11/2900.00284.2084.30-2524-0.38%
2024/11/1100.00180.5082.40-1533-0.19%
2024/11/06281.0000.0080.8025280.38%
2024/10/2900.00280.9080.90-2588-0.34%
2024/10/25281.5000.0081.4025670.35%
2024/07/2600.00185.9085.80-1735-0.14%
2024/07/2300.00187.3086.50-1746-0.13%
2024/07/22187.1000.0087.1017450.13%
2024/07/19289.95288.2086.5007270.00%
2024/07/05287.1500.0086.8028560.23%
2024/06/1900.00090.2089.5001,1360.00%
2024/06/1200.000.291.2091.00-0.21,174-0.01%
2024/06/0700.00790.0090.10-71,167-0.60%
2024/06/0500.00590.5090.30-51,237-0.40%
2024/06/03189.5000.0089.6011,3860.07%
2024/05/29990.5800.0089.1091,5110.60%
2024/05/1500.00286.7086.40-22,211-0.09%
中裕首度與美國客戶簽訂CDMO合約 營運添動能Anue鉅亨-13天前
〈美對等關稅〉中裕回應暫無影響 愛滋病新藥足以供應美國市場銷售Anue鉅亨-2025/04/09
中裕長效愛滋療法主要指標達標 啟動國際授權合作Anue鉅亨-2025/03/26
中裕 相關文章